FY2025 EPS Estimates for Q32 Bio Boosted by Leerink Partnrs

Q32 Bio Inc. (NASDAQ:QTTB - Free Report) - Investment analysts at Leerink Partnrs lifted their FY2025 earnings per share estimates for shares of Q32 Bio in a research report issued on Wednesday, December 11th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings per share of ($3.38) for the year, up from their previous forecast of ($5.32). Leerink Partnrs currently has a "Hold" rating on the stock. The consensus estimate for Q32 Bio's current full-year earnings is ($12.20) per share. Leerink Partnrs also issued estimates for Q32 Bio's FY2026 earnings at ($3.11) EPS, FY2027 earnings at ($3.62) EPS and FY2028 earnings at ($2.50) EPS.

QTTB has been the subject of a number of other research reports. BMO Capital Markets decreased their price target on shares of Q32 Bio from $64.00 to $22.00 and set an "outperform" rating for the company in a research note on Thursday. Raymond James restated an "outperform" rating and set a $22.00 price objective (down previously from $90.00) on shares of Q32 Bio in a report on Wednesday. Wells Fargo & Company restated an "equal weight" rating and set a $16.00 price objective (down previously from $95.00) on shares of Q32 Bio in a report on Wednesday. Piper Sandler lowered their price objective on shares of Q32 Bio from $85.00 to $20.00 and set an "overweight" rating on the stock in a report on Wednesday. Finally, Oppenheimer lowered their price objective on shares of Q32 Bio from $80.00 to $20.00 and set an "outperform" rating on the stock in a report on Wednesday. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Q32 Bio presently has a consensus rating of "Moderate Buy" and an average price target of $29.86.

Q32 Bio Stock Down 11.1 %

NASDAQ:QTTB traded down $0.47 on Friday, hitting $3.78. The stock had a trading volume of 1,104,239 shares, compared to its average volume of 101,863. The company has a quick ratio of 6.53, a current ratio of 6.53 and a debt-to-equity ratio of 0.61. Q32 Bio has a 52 week low of $3.75 and a 52 week high of $53.79. The business's fifty day moving average is $37.63 and its 200 day moving average is $34.28. The company has a market cap of $46.04 million, a PE ratio of -0.28 and a beta of -0.46.

Hedge Funds Weigh In On Q32 Bio

Several institutional investors have recently added to or reduced their stakes in the stock. Values First Advisors Inc. purchased a new stake in Q32 Bio during the third quarter valued at about $33,000. BNP Paribas Financial Markets lifted its holdings in shares of Q32 Bio by 199.1% in the third quarter. BNP Paribas Financial Markets now owns 1,298 shares of the company's stock worth $58,000 after buying an additional 864 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Q32 Bio by 11,681.5% in the second quarter. Rhumbline Advisers now owns 7,658 shares of the company's stock worth $137,000 after buying an additional 7,593 shares in the last quarter. MetLife Investment Management LLC purchased a new stake in shares of Q32 Bio in the third quarter worth about $159,000. Finally, Franklin Resources Inc. purchased a new stake in shares of Q32 Bio in the third quarter worth about $225,000. Institutional investors own 31.32% of the company's stock.

About Q32 Bio

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.